CRIS - Curis Inc logo

Curis Inc

CRIS

Curis Inc is a biotechnology company focused on developing drug candidates for cancer treatment. Its pipeline includes drugs for various cancers, with collaborations for commercializing Erivedge and advancements in immuno-oncology and precision oncology.

βš•οΈ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 20 years ago β†’$0today

Score Overview

1 Year
Score
Net Growth-178.99%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-54.32%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score4.4
Net Growth53.44%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth-59.49%
Rev Trend20%
Revenue Consistencyβ€”
10 Years
Score
Net Growth64.98%
Net Trend70%
Net Income Consistency
Rev Growth-42.69%
Rev Trend40%
Revenue Consistency
20 Years
Score2.4
Net Growth-139.58%
Net Trend55%
Net Income Consistency
Rev Growth-71.12%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth93.96%
Net Trend54%
Net Income Consistency
Rev Growth332.66%
Rev Trend46%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Curis Inc has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CRIS

2006: 79.5% Β· 2021: 29.4% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.83β€”
1 Year2025-09-29
$ 33.20-97.50%
5 Years2021-09-29
$ 3.11K-99.97%
10 Years2016-09-29
$ 4.94K-99.98%
20 Years2006-09-29
$ 2.74K-99.97%
All Time2000-08-01
$ 48.75K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 4M-$ 21M$ 5M
2025$ 9M-$ 7M$ 5M
2024$ 10M-$ 43M$ 19M
2023$ 10M-$ 47M$ 56M
2022$ 10M-$ 60M$ 85M
2021$ 10M-$ 45M$ 115M
2020$ 10M-$ 29M$ 168M
2019$ 10M-$ 32M$ 20M
2018$ 10M-$ 32M$ 24M
2017$ 9M-$ 53M$ 60M
2016$ 7M-$ 60M$ 44M
2015$ 7M-$ 58M$ 82M
2014$ 9M-$ 18M$ 50M
2013$ 15M-$ 12M$ 68M
2012$ 16M-$ 16M$ 58M
2011$ 14M-$ 9M$ 235.91K
2010$ 15M-$ 4M$ 40M
2009$ 8M-$ 9M$ 25M
2008$ 8M-$ 12M$ 28M
2007$ 16M-$ 6M$ 41M
2006$ 14M-$ 8M$ 36M
2005$ 6M-$ 14M$ 44M
2004$ 4M-$ 13M$ 49M
2003$ 11M-$ 11M$ 35M
2002$ 18M-$ 82M$ 40M
2001$ 1M-$ 81M$ 52M
IPO2000$ 997.08K-$ 350M$ 75M
CRIS - Curis Inc logo

Curis Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 10M to $ 9M and net income went from -$ 29M to -$ 7M. Revenue increased in 1 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 7M to $ 9M and net income went from -$ 58M to -$ 7M. Revenue increased in 4 of those 10 years; net income in 7.

Curis Inc currently holds a 20-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.

Membership

Continue CRIS’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies